Previous 10 | Next 10 |
EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED ® , a subcutaneous testosterone enanthate injection, was accepted as on oral presentatio...
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens...
EWING, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that it entered into an exclusive license agreement with Lipocine Inc. (“Lipocine”), a clinical-stage biopharma...
EWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for ATRS-1902 for adrenal crisis rescue. The development program supports a proposed i...
EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwri...
Antares Pharma, Inc. (ATRS) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Tram Bui – Vice President-Corporate Communications and Investor Relations Bob Apple – President and Chief Executive Officer Joe Renda – Senior Vice President-Commer...
The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Antares Pharma, Inc. 2021 Q2 - Results - Earnings Call Presentation
Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceu...
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens....
EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 fo...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...